Vascepa, also known as icosapent ethyl, is a prescription medication used to reduce triglyceride levels in certain patients. According to a press release by the FDA [3], Vascepa has been approved to reduce the risk of cardiovascular events in adult patients with elevated triglyceride levels (150 mg/dL or higher) and other risk factors. The drug is effective in reducing triglyceride levels by up to 33% [2].

Vascepa is a purified form of eicosapentaenoic acid (EPA), which is an omega-3 fatty acid found in fish oil. Unlike Lovaza, another prescription omega-3 medication, Vascepa does not contain docosahexaenoic acid (DHA) [2]. According to a study cited on Drug Patent Watch [1], Vascepa was found to be more effective than Lovaza in reducing triglyceride levels in patients with severe hypertriglyceridemia.

In conclusion, Vascepa is an effective medication for reducing triglyceride levels in certain patients, with up to a 33% reduction in levels. It has been approved by the FDA to reduce the risk of cardiovascular events in adult patients with elevated triglyceride levels and other risk factors. Additionally, Vascepa has been found to be more effective than Lovaza in reducing triglyceride levels in patients with severe hypertriglyceridemia.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.goodrx.com/icosapent-ethyl/lovaza-vascepa-lowering-triglycerides
[3] https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups